- Home
- IOTR vs RANI Comparison
IOTR vs RANI Comparison
Compare IOTR & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOTR
- RANI
- Stock Information
- Founded
- IOTR 2019
- RANI 2012
- Country
- IOTR Singapore
- RANI United States
- Employees
- IOTR N/A
- RANI N/A
- Industry
- IOTR
- RANI Medicinal Chemicals and Botanical Products
- Sector
- IOTR
- RANI Health Care
- Exchange
- IOTR NYSE
- RANI Nasdaq
- Market Cap
- IOTR 29.5M
- RANI 28.1M
- IPO Year
- IOTR 2025
- RANI 2021
- Fundamental
- Price
- IOTR $0.41
- RANI $0.56
- Analyst Decision
- IOTR
- RANI Strong Buy
- Analyst Count
- IOTR 0
- RANI 5
- Target Price
- IOTR N/A
- RANI $8.20
- AVG Volume (30 Days)
- IOTR 671.5K
- RANI 861.5K
- Earning Date
- IOTR 01-01-0001
- RANI 05-13-2025
- Dividend Yield
- IOTR N/A
- RANI N/A
- EPS Growth
- IOTR N/A
- RANI N/A
- EPS
- IOTR N/A
- RANI N/A
- Revenue
- IOTR $9,578,336.00
- RANI $1,200,000.00
- Revenue This Year
- IOTR N/A
- RANI $24,705.45
- Revenue Next Year
- IOTR N/A
- RANI N/A
- P/E Ratio
- IOTR N/A
- RANI N/A
- Revenue Growth
- IOTR 13.93
- RANI N/A
- 52 Week Low
- IOTR $0.31
- RANI $0.46
- 52 Week High
- IOTR $5.98
- RANI $5.38
- Technical
- Relative Strength Index (RSI)
- IOTR N/A
- RANI 33.63
- Support Level
- IOTR N/A
- RANI $0.46
- Resistance Level
- IOTR N/A
- RANI $0.59
- Average True Range (ATR)
- IOTR 0.00
- RANI 0.05
- MACD
- IOTR 0.00
- RANI 0.01
- Stochastic Oscillator
- IOTR 0.00
- RANI 18.50
About RANI Rani Therapeutics Holdings Inc.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.